Trials
Search / Trial NCT05650827

Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer

Launched by RIGSHOSPITALET, DENMARK · Dec 12, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Recruiting

Keywords

Exercise Oncology Resistance Exercise Cancer Cancer Cachexia Protein Supplements Sarcopenia Palliative Chemotherapy

ClinConnect Summary

This clinical trial is looking at how resistance training (like weight lifting) and protein supplements might help patients with advanced gastroesophageal cancer, a type of cancer that affects the esophagus and stomach. Many patients with this condition lose muscle mass, which can make them feel weaker and affect their quality of life. The goal of the study is to see if combining regular exercise and protein supplements with standard cancer care can improve muscle health and overall well-being during their first round of chemotherapy.

To participate in the trial, patients need to be adults aged 18 and older who have been diagnosed with advanced gastroesophageal cancer and are set to begin their first chemotherapy treatment. They will be randomly assigned to either a group that receives standard care along with resistance training and protein supplements, or a group that only receives standard care. The study is currently recruiting participants and aims to find out if this approach is safe and effective for improving muscle strength and health in these patients. If you're considering joining the trial, it's important to know that there are specific criteria you must meet, such as being able to swallow liquids and not having other active cancers requiring treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • histologically verified, non-resectable cancer of the esophagus, stomach, or gastroesophageal junction
  • • referred to first line chemotherapy.
  • Exclusion Criteria:
  • • Age \< 18
  • • Living outside the greater Copenhagen area
  • • Any other malignancy requiring active treatment
  • • Not eligible for chemotherapy
  • • Performance status \> 2
  • • Not able to swallow liquids
  • • Parenteral nutrition or enteral nutrition via feeding tube
  • • Physical or mental disabilities that prohibit execution of test or training procedures
  • • Pregnancy
  • • Inability to understand the Danish language

Trial Officials

Casper Simonsen, PhD

Principal Investigator

Copenhagen University Hospital, Rigshospitalet, Denmark

About Rigshospitalet, Denmark

Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.

Locations

Copenhagen, , Denmark

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials